Kenvue has announced a major overhaul of its global advertising ecosystem, appointing WPP and Publicis Groupe as its new worldwide agency partners following a competitive review that began earlier this year. The move marks a significant shift in how the consumer health giant plans to drive brand growth, consistency, and coordination across its expansive portfolio.

Under the new structure, WPP will oversee creative development and production across channels for all Kenvue brands, with the exception of Neutrogena. Publicis Groupe will lead global media, commerce, healthcare communications, and technology services, while also handling creative and production responsibilities for Neutrogena. Publicis already manages Kenvue’s media operations in the Asia-Pacific region, providing continuity within the revised setup.

The review encompassed Kenvue’s flagship brands, including Tylenol, Listerine, and Neutrogena. According to COMvergence estimates, Kenvue’s global media spend stood at approximately $1.35 billion in 2025, highlighting the scale and strategic importance of the account.

Previously, Kenvue’s advertising business was split across Omnicom agencies BBDO and Interpublic Group agencies FCB and UM. That arrangement evolved following Omnicom’s acquisition of Interpublic Group in November, which effectively consolidated the incumbent agencies under one holding company prior to the review.

Spun off from Johnson & Johnson in 2023, Kenvue continues to refine its brand-building approach as an independent entity. The appointment of WPP and Publicis signals a renewed focus on tighter integration between creativity, media, data, and technology-particularly critical as key brands like Tylenol navigate a phase of both expansion and operational complexity.

With this streamlined dual-holding-company model, Kenvue aims to unlock stronger global alignment, sharper execution, and sustainable growth across its diverse consumer health portfolio.